Farhan A. Syed, Ph.D., David Bennett, Ph.D., Michael O’Connor, Ph.D., Gabriele Pradella, and Sarah Warner, Ph.D.
Presented at the American College of Rheumatology Annual Convergence, 2018
Phase 2 and phase 3 trials in Axial Spondyloarthritis (AxSpA) require the assessment of the sacro-iliac joint (SIJ) either by X-ray or MRI or both in conjunction to establish if the disease is non-radiographic (nr- AxSpA) or radiographic ankylosing spondylitis (AS).
Therefore, for prospective trial design it is important to understand the percentages of subjects likely to be deemed eligible by central imaging review and how many subjects will screen-fail for either AS (mNY+) or nr-AxSpA (mNY-).
